英派药业-B

开始申购 2026-05-05

未上市

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
英派药业－Ｂ
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
https://www.impacttherapeutics.com/
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
英派药业致力于研发具有自主知识产权的靶向抗癌创新药,专注于合成致死作用机制。公司以DNA损伤修复通路(DDR)自主研发产品为基础,构建了全球生物医药公司中覆盖面最广的DDR产品管线之一,并且正在逐步拓展到更多的全新的合成致死靶点。公司管线包括PARP抑制剂塞纳帕利(Senaparib/IMP4297)、Wee1抑制剂(IMP7068)、ATR抑制剂(IMP9064)、PARP1选择性抑制剂(IMP1734,与美国Eikon Therapeutics合作开发)以及多个其他DDR靶点抑制剂。其中最成熟的研发项目PARP抑制剂塞纳帕利在全球范围包含中国已开展卵巢癌、小细胞肺癌等适应症的临床II/III期研究。塞纳帕利用于晚期卵巢癌全人群一线维持治疗的III期临床研究(FLAMES)已达到主要研究终点,显示了同类最佳的药效和安全性。基于FLAMES研究成果,中国国家药监局(NMPA)已于2025年1月批准了塞纳帕利的新药上市申请。Wee1抑制剂IMP7068和ATR抑制剂IMP9064已在包括美国、中国在内的全球多个国家及地区开展I期临床研究,确定了临床II期推荐剂量(RP2D)。PARP1选择性抑制剂IMP1734已经获得FDA和NMPA的临床试验许可,在2024年初完成第一例患者入组。
- 05-05
  股份发售
  全球发售
  全球发售

2026-05-05

招股说明书查看招股说明书

2026-05-05

发行信息

价格范围
19.750 - 21.750HKD
发售规模
276.17M
市值
5.45B-6.01B
最小购买量
200
杠杆率
待定

2026-05-08

已休市

发行价格
待定

2026-05-12

中签日

抽签率
待定

2026-05-13

上市

热议股票

{"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"07630","data":{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":0,"timestamp":1778227200000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":234000000,"shares":276000000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"05-08 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.231,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":8,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1778203800000,1778212800000],[1778216400000,1778227200000]],"volumeRatio":0,"ipoDetail":{"name":"英派药业－Ｂ","exchange":"SEHK","listingDate":"2026-05-13","sharesOutstanding":276165130,"sharesFloat":276165130,"offerAmount":41977000,"priceRange":"19.750 - 21.750","market":"HK","openProspectusDate":"2026-05-05","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0505/2026050500024_c.pdf","purchaseBeginDate":"2026-05-05","purchaseEndDate":"2026-05-08","winningDate":"2026-05-12","currency":"HKD","minPurchaseQuantity":200,"peRate":-17.52,"use":"1、约51%或398.37百万港元将用于为核心产品塞纳帕利正在进行及计划中的临床开发、监管批准以及商业化提供资金；\n2、约31%或242.15百万港元将用于为关键产品IMP1734及IMP9064正在进行的临床开发提供资金；\n3、约8%或62.49百万港元将用于为其他管线资产、IMP1707、IMP7068、IMP22、IMP25、IMP08、IMP13及IMP10的研发活动提供资金；\n4、约8%或62.49百万港元将用于为研发平台的开发及扩大药物管线提供资金；\n5、约2%或15.62百万港元将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家处于商业化阶段的创新驱动型生物技术公司，致力于在全球范围内推进基于合成致死(synthetic lethality)机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌一线维持疗法，适用于全人群（无论突变状态），并展现出令人信服的临床特征。通过整合小分子药物与新兴疗法（包括新型抗体偶联药物和蛋白降解剂）的自主研发平台，公司持续推动创新突破。","subscribed":1388.04,"marketCap":5454000000,"minimumCapital":4393.88,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,1250000,1500000,1750000,2098800","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-05-12","greyDateTimestamp":1778515200000,"greyOpeningTime":1778573700000,"greyClosingTime":1778581800000,"showGreyQuote":false,"openProspectusDate":"2026-05-05","listingDate":"2026-05-13"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.561586843509160","cardData":[{"tweetId":"561586843509160","author":{"authorId":"4116305654989300","idStr":"4116305654989300","name":"证悟君","avatar":"https://static.tigerbbs.com/f7ba3b0f9a9be12f0cca8e1eb04baca4","userType":2,"introduction":"港股之感悟，新股之心得","crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.08","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[],"fanSize":1019,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"剂泰打新 如果我资金充足，先打满&nbsp;<a href=\"https://ttm.financial/S/07666\">$剂泰科技-P(07666)$ </a>&nbsp; ，再顶英派。 如果我乙头或以下，看认购比，10倍以内打剂泰，10倍以上打英派。（比如剂泰6000倍，英派500倍，那我会allin&nbsp;<a href=\"https://ttm.financial/S/07630\">$英派药业-B(07630)$ </a>&nbsp; ）","plainDigest":"剂泰打新 如果我资金充足，先打满 $剂泰科技-P(07666)$ ，再顶英派。 如果我乙头或以下，看认购比，10倍以内打剂泰，10倍以上打英派。（比如剂泰6000倍，英派500倍，那我会allin $英派药业-B(07630)$ ）","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778137981034,"gmtModify":1778139947197,"symbols":["07666","07630"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":11652,"likeCount":7,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561586843509160","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":171,"displayRows":4,"foldSize":0,"authorId":"4116305654989300"}]},{"cardType":"TWEET","cardId":"TWEET.561778354557216","cardData":[{"tweetId":"561778354557216","author":{"authorId":"4182483484134852","idStr":"4182483484134852","name":"天行小子","avatar":"https://community-static.tradeup.com/news/706a8447d83bfa5a67c13df6075e33c1","userType":1,"introduction":"","crmLevel":13,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":64,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":55,"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"userFollowInvestorFlag":false,"ror":6.94,"showRor":true,"winRationPercentage":91.304348,"dataLabelList":[],"tradeVolumeEst":0},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"userFollowInvestorFlag":false,"title":"","digest":"<a href=\"https://ttm.financial/S/07630\">$英派药业-B(07630)$&nbsp;</a><v-v data-views=\"1\"></v-v> 和<a href=\"https://ttm.financial/S/07666\">$07666(07666)$&nbsp;</a><v-v data-views=\"1\"></v-v> 揰期，唉，含硬泪平其他仓抽你地，要乖乖听话生性，五月ipo我仲未开斋[回头]&nbsp;&nbsp;","plainDigest":"$英派药业-B(07630)$ 和$07666(07666)$ 揰期，唉，含硬泪平其他仓抽你地，要乖乖听话生性，五月ipo我仲未开斋[回头]","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778184625634,"gmtModify":1778184631889,"symbols":["07666","07630"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://community-static.tradeup.com/news/08537cdc84721f77e5aa21cc426ffa14","width":"825","height":"1434"}],"repostCount":0,"viewCount":628,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561778354557216","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":102,"displayRows":4,"foldSize":0,"authorId":"4182483484134852"}]},{"cardType":"TWEET","cardId":"TWEET.561591047979104","cardData":[{"tweetId":"561591047979104","author":{"authorId":"4210770507899382","idStr":"4210770507899382","name":"雪哥观澜","avatar":"https://static.tigerbbs.com/0f8d237ac2186b5c2410e880bdcbb1c8","userType":2,"introduction":"10 余年金融投资实战经验，专注港股、美股市场研究与 IPO 打新策略分析","crmLevel":4,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.30","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","name":"博闻投资者","description":"累计交易超过10只正股","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":276,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"英派药业-B（07630）vs 剂泰科技-P（07666","digest":"乐动资金马上回来了，一个B一个P谁更优秀？ 文章原文","plainDigest":"乐动资金马上回来了，一个B一个P谁更优秀？ 文章原文","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778138940000,"gmtModify":1778140032069,"symbols":["07666","07630"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/b3a722ce6ed54cf496d39625f210a183"},{"url":"https://static.tigerbbs.com/73a8eb4dd9454c41af07336491dd946c"},{"url":"https://static.tigerbbs.com/7dcbb8b5ce0a49bea3107ee71b7e6681"}],"repostCount":0,"viewCount":3410,"likeCount":5,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561591047979104","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":46,"displayRows":4,"foldSize":0,"authorId":"4210770507899382"}]},{"cardType":"TWEET","cardId":"TWEET.561653458282432","cardData":[{"tweetId":"561653458282432","author":{"authorId":"4210899891839960","idStr":"4210899891839960","name":"胡萝卜1","avatar":"https://static.tigerbbs.com/3790c64893f99f0d14990b8ae49a9ad3","userType":1,"introduction":"","crmLevel":8,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.24","exceedPercentage":"80.64%","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/07630\">$英派药业-B(07630)$</a> 快来吧，我推荐","plainDigest":"$英派药业-B(07630)$ 快来吧，我推荐","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778154204358,"gmtModify":1778158558853,"symbols":["07630"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":87,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561653458282432","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":32,"displayRows":4,"foldSize":0,"authorId":"4210899891839960"}]},{"cardType":"TWEET","cardId":"TWEET.561467493892448","cardData":[{"tweetId":"561467493892448","author":{"authorId":"3498690247998564","idStr":"3498690247998564","name":"二狗叨叨","avatar":"https://static.tigerbbs.com/55e1bdc35fbca55dc650568445c5703e","userType":1,"introduction":"","userGiftHeadFrame":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":1972,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【港股打新】英派药业-B 申购策略","digest":"图片一、基本信息<a href=\"https://laohu8.com/S/07630\">$英派药业-B(07630)$</a> ，成立于2009年，是一家处于商业化阶段的生物技术公司，致力于在全球范围内推进基于合成致死机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。。。公司通过自主研发建立了最全面、最先进的合成致死产品组合之一，也是全球仅有的三家同时拥有商业化阶段的PARP1/2抑制剂和临床阶段新一代PARP1选择性抑制剂的公司之一。。。公司已搭建双载荷抗体偶联药物（ADC）平台及蛋白降解剂平台，研发管线覆盖PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等关键合成致死靶点的小分子抑制剂，以及CEACAM5双载荷抗体偶联药物和KAT6A选择性蛋白降解剂。。。核心产品塞纳帕利（IMP4297）于2025年1月获批用于中国卵巢癌 “全人群” 一线维持治疗后正式启动商业化，并自2026年1月1日起纳入国家医保药品目录。塞纳帕利在中国卵巢癌 “全人群” 一线维持治疗的 PARP1/2 抑制剂中（非头对头研究）中实现了最有利的PFS结果，为该类药物树立了新标杆。。。。二、招股信息公司名称及代码：英派药业-B（07666.HK）招股价：10.50KD入场费：5302.95HKD（1手500股）招股日期：05月05至05月08日，本周五截止公布中签：05月11日上市：05月13日发售股份：2.02亿股，占总股本17.46%分配机制：机制B市值：121.01亿HKD绿鞋：有。。。基石：8名基石共认购占比32.15%，阵容还算不错保荐人：高盛、中金！三、基本面情况公司在2022年、2023年和2024年，实现营收分别约为2.35亿元、0.34亿元、0.38亿，期间公司净利润分别为-0.20亿元、-2.55亿元","plainDigest":"图片一、基本信息$英派药业-B(07630)$ ，成立于2009年，是一家处于商业化阶段的生物技术公司，致力于在全球范围内推进基于合成致死机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。。。公司通过自主研发建立了最全面、最先进的合成致死产品组合之一，也是全球仅有的三家同时拥有商业化阶段的PARP1/2抑制剂和临床阶段新一代PARP1选择性抑制剂的公司之一。。。公司已搭建双载荷抗体偶联药物（ADC）平台及蛋白降解剂平台，研发管线覆盖PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等关键合成致死靶点的小分子抑制剂，以及CEACAM5双载荷抗体偶联药物和KAT6A选择性蛋白降解剂。。。核心产品塞纳帕利（IMP4297）于2025年1月获批用于中国卵巢癌 “全人群” 一线维持治疗后正式启动商业化，并自2026年1月1日起纳入国家医保药品目录。塞纳帕利在中国卵巢癌 “全人群” 一线维持治疗的 PARP1/2 抑制剂中（非头对头研究）中实现了最有利的PFS结果，为该类药物树立了新标杆。。。。二、招股信息公司名称及代码：英派药业-B（07666.HK）招股价：10.50KD入场费：5302.95HKD（1手500股）招股日期：05月05至05月08日，本周五截止公布中签：05月11日上市：05月13日发售股份：2.02亿股，占总股本17.46%分配机制：机制B市值：121.01亿HKD绿鞋：有。。。基石：8名基石共认购占比32.15%，阵容还算不错保荐人：高盛、中金！三、基本面情况公司在2022年、2023年和2024年，实现营收分别约为2.35亿元、0.34亿元、0.38亿，期间公司净利润分别为-0.20亿元、-2.55亿元","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778108720139,"gmtModify":1778118968463,"symbols":["07666","01236","07630","01609"],"themeIds":["e4363384c4254650b897c0f13fe1588f"],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/f81e8aebd67a7870c009231a177f8c11"}],"repostCount":0,"viewCount":11589,"likeCount":4,"liked":false,"collected":false,"commentCount":2,"hotComments":[{"id":"561697017128144","author":{"authorId":"3548712052573855","idStr":"3548712052573855","name":"稻草人的风筝","avatar":"https://static.tigerbbs.com/bbe8c366cd157bd0ed68672768c0b052","userType":1,"introduction":"","crmLevel":3,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false},"content":"什么意思，三个账户，两个全额融资，一个现金摸，全打英派，不打剂泰科技吗？","plainContent":"什么意思，三个账户，两个全额融资，一个现金摸，全打英派，不打剂泰科技吗？","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561467493892448","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":1969,"displayRows":4,"foldSize":0,"authorId":"3498690247998564"}]},{"cardType":"TWEET","cardId":"TWEET.561293893145528","cardData":[{"tweetId":"561293893145528","author":{"authorId":"3562180434469741","idStr":"3562180434469741","name":"小散老俞","avatar":"https://static.tigerbbs.com/a018a5241bf0efc6e637e677f026036d","userType":2,"introduction":"专注于港股打新的价值投资者！","crmLevel":1,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.31","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.08","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000}],"fanSize":1960,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【港股打新】英派药业，国内合成致死赛道龙头","digest":"&nbsp; &nbsp;英派药业致力于在全球范围内推进基于合成致死(synthetic lethality)机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。通俗的讲就是专门生产精准靶向抗癌药的生物公司，主打 “只杀癌细胞、尽量不伤正常细胞” 的新型化疗药。是国内合成致死赛道龙头、全球第一梯队。 &nbsp; 公司5月5日开始招股，招股价19.75~2.75港元，每手股数200股，最低认购4393.88港元，市值54.54亿~60.07亿港元，发行数量4197.7万股，属于生物技术行业，有绿鞋。 &nbsp; &nbsp;保荐人是高盛亚洲和中金公司，高盛亚洲近2年保荐的项目首日上涨率是58.33%；中金公司近2年保荐的项目首日上涨率是71.92%，保荐人整体业绩还不错。 &nbsp; &nbsp;一共有6名基石投资者，包括南京生物医药谷（BPV）+ 华泰资本、腾讯控股、礼来亚洲基金、睿远基金、上弦月基金、Worldwide Healthcare Partners；基石合计共认购3574万美元，占总发行数的32.15%，基石占比还可以。 &nbsp; &nbsp; 公司有一款核心产品塞纳帕利（派舒宁 ®）已实现商业化。在2025 年 1 月获 NMPA 批准上市，用于卵巢癌全人群一线维持治疗。其他产品都还在研发阶段。 &nbsp; &nbsp;公司从2023~2025年的营收分别是2.35亿、3354.7万、3825.1万，2025年营收同比增长14.02%；2023~2025年的净利润分别是-1993.8万、-2.55亿、-2.96亿，2025年的净利润同比增长-16.16%。 &nbsp; &nbsp; 按发行价中位数计算，57.31亿港元市值发行8.71亿，发行比例是15.2%，基石锁定32.15%，那么流通盘是5.91亿。 &nbsp; &nbsp;","plainDigest":"英派药业致力于在全球范围内推进基于合成致死(synthetic lethality)机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。通俗的讲就是专门生产精准靶向抗癌药的生物公司，主打 “只杀癌细胞、尽量不伤正常细胞” 的新型化疗药。是国内合成致死赛道龙头、全球第一梯队。 公司5月5日开始招股，招股价19.75~2.75港元，每手股数200股，最低认购4393.88港元，市值54.54亿~60.07亿港元，发行数量4197.7万股，属于生物技术行业，有绿鞋。 保荐人是高盛亚洲和中金公司，高盛亚洲近2年保荐的项目首日上涨率是58.33%；中金公司近2年保荐的项目首日上涨率是71.92%，保荐人整体业绩还不错。 一共有6名基石投资者，包括南京生物医药谷（BPV）+ 华泰资本、腾讯控股、礼来亚洲基金、睿远基金、上弦月基金、Worldwide Healthcare Partners；基石合计共认购3574万美元，占总发行数的32.15%，基石占比还可以。 公司有一款核心产品塞纳帕利（派舒宁 ®）已实现商业化。在2025 年 1 月获 NMPA 批准上市，用于卵巢癌全人群一线维持治疗。其他产品都还在研发阶段。 公司从2023~2025年的营收分别是2.35亿、3354.7万、3825.1万，2025年营收同比增长14.02%；2023~2025年的净利润分别是-1993.8万、-2.55亿、-2.96亿，2025年的净利润同比增长-16.16%。 按发行价中位数计算，57.31亿港元市值发行8.71亿，发行比例是15.2%，基石锁定32.15%，那么流通盘是5.91亿。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778066341392,"gmtModify":1778072230895,"symbols":["07666","07630"],"themeIds":["bbff91dc17c14a06a84c8b103cf4e290"],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/c019dd183238b74ec3c29acf611e20f9","width":"600","height":"355"},{"url":"https://static.tigerbbs.com/81a40f28741b0902ded9d8677df3d6b2","width":"1080","height":"539"},{"url":"https://static.tigerbbs.com/c994ef509e2d3f96665c3e99b191c0f0","width":"847","height":"657"}],"repostCount":2,"viewCount":11785,"likeCount":4,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561293893145528","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":1830,"displayRows":4,"foldSize":0,"authorId":"3562180434469741"}]},{"cardType":"TWEET","cardId":"TWEET.561586457825440","cardData":[{"tweetId":"561586457825440","author":{"authorId":"3468677072884748","idStr":"3468677072884748","name":"爱投资的小熊猫","avatar":"https://static.tigerbbs.com/161807d4571cc1775f29fd24a2eaac9c","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5335,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"英派药业-B，撞车剂泰科技，是市场化or搞事情？——(07630.HK)2026年5月新股分析","digest":"<a href=\"https://laohu8.com/S/07630\">$英派药业-B(07630)$</a> 保荐人：高盛（亚洲）有限责任公司 &nbsp;中国国际金融香港证券有限公司 &nbsp;&nbsp; 招股价格：19.75-21.75港元 集资额： 8.29亿-9.13亿港元 总市值： 54.54亿-60.07亿港元 H股市值： 54.54亿-60.07亿港元 每手股数 200股&nbsp; 入场费 &nbsp;4393.88港元 招股日期 2026年05月05日—2026年05月08日 暗盘时间：2026年05月12日 上市日期：2026年05月13日（星期三） 招股总数 4197.70万股H股 国际配售 3777.92万股H股，约占 90.00%&nbsp; 公开发售 419.78万股H股，约占10.00% 分配机制 机制B 计息天数：3天 稳价人 &nbsp;高盛 发行比例 15.20% 市盈率 &nbsp;-17.52 公司简介&nbsp; 英派药业成立于2009年，是已迈入商业化阶段的创新生物技术企业，专注全球合成致死精准抗癌药物研发，填补肿瘤临床未被满足的治疗需求。 合成致死是前沿肿瘤治疗机制，双通路缺陷才可诱导癌细胞凋亡，相较传统疗法可攻克难成药靶点、解决耐药难题，适配联合用药，安全性与治疗窗口更优，PARP抑制剂已验证该赛道临床与商业价值，行业新靶点、资本投入持续推动赛道高速发展 。 公司核心自研产品塞纳帕利（IMP4297），为差异化PARP1/2抑制剂，2025年1月于国内获批卵巢癌全人群一线维持治疗并正式商业化，III期临床数据刊发于《自然医学》，无进展生存期获益显著、安全性优异。该药同步拓展多适应症：BRCA突变卵巢癌二线单药（II期完成）、小细胞肺癌联合用药、PARP抑制剂耐药卵巢癌联合治疗等 。 公司管线布局完善，合计11款自研候选","plainDigest":"$英派药业-B(07630)$ 保荐人：高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招股价格：19.75-21.75港元 集资额： 8.29亿-9.13亿港元 总市值： 54.54亿-60.07亿港元 H股市值： 54.54亿-60.07亿港元 每手股数 200股 入场费 4393.88港元 招股日期 2026年05月05日—2026年05月08日 暗盘时间：2026年05月12日 上市日期：2026年05月13日（星期三） 招股总数 4197.70万股H股 国际配售 3777.92万股H股，约占 90.00% 公开发售 419.78万股H股，约占10.00% 分配机制 机制B 计息天数：3天 稳价人 高盛 发行比例 15.20% 市盈率 -17.52 公司简介 英派药业成立于2009年，是已迈入商业化阶段的创新生物技术企业，专注全球合成致死精准抗癌药物研发，填补肿瘤临床未被满足的治疗需求。 合成致死是前沿肿瘤治疗机制，双通路缺陷才可诱导癌细胞凋亡，相较传统疗法可攻克难成药靶点、解决耐药难题，适配联合用药，安全性与治疗窗口更优，PARP抑制剂已验证该赛道临床与商业价值，行业新靶点、资本投入持续推动赛道高速发展 。 公司核心自研产品塞纳帕利（IMP4297），为差异化PARP1/2抑制剂，2025年1月于国内获批卵巢癌全人群一线维持治疗并正式商业化，III期临床数据刊发于《自然医学》，无进展生存期获益显著、安全性优异。该药同步拓展多适应症：BRCA突变卵巢癌二线单药（II期完成）、小细胞肺癌联合用药、PARP抑制剂耐药卵巢癌联合治疗等 。 公司管线布局完善，合计11款自研候选","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778137760672,"gmtModify":1778137832345,"symbols":["07630"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":15,"images":[{"url":"https://static.tigerbbs.com/667468ef3ddf9e0c7a75897ab02a2152","width":"939","height":"832"}],"repostCount":1,"viewCount":7545,"likeCount":2,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"561597009662768","author":{"authorId":"3479274765978906","idStr":"3479274765978906","name":"NING667","avatar":"https://static.laohu8.com/picture94","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":11,"starInvestorFlag":false},"content":"筹码不锁的话 首日谁接","plainContent":"筹码不锁的话 首日谁接","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561586457825440","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":7619,"displayRows":4,"foldSize":0,"authorId":"3468677072884748"}]},{"cardType":"TWEET","cardId":"TWEET.561271109853472","cardData":[{"tweetId":"561271109853472","author":{"authorId":"4204409696979492","idStr":"4204409696979492","name":"101可转债","avatar":"https://static.tigerbbs.com/e9fd1abc154a52b8356f64c64f49564d","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","templateUuid":"a97bce155cb14045be40c3fe246e8d20","name":"Emerging Contributor","description":"Contributors who received Editor's Pick for the 1st time","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.13","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.08","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","name":"新晋创作者","description":"首次获得精华帖的创作者","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":404,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"港股新股打新：剂泰科技 - P (07666.HK) AI药物递送第一股+中签预测","digest":"<a href=\"https://laohu8.com/S/07666\">$剂泰科技-P(07666)$</a> <a href=\"https://laohu8.com/S/07630\">$英派药业-B(07630)$</a> 基本情况： 申购时间：5月5日-5月8日，11号出结果，12号暗盘，13号上市； 发行价格：10.5 入场费：5302.95 1手：500股 全球发售：2.01亿股 回拨5%：公开发售：1006.15万股，发行手数：20123手； 回拨10%：公开发售：2012.30万股，发行手数：40246手； 回拨20%：公开发售：4024.60万股，发行手数：80492手； 基石：有，18家基石投资者认购54.84%份额 绿鞋：有，中信里昂稳价 保荐人：富瑞、德意志、中信联合保荐 分配机制：18C机制A，最高回拨20% 剂泰科技是一家人工智能驱动纳米材料创新的生物科技公司，由美国工程院院士陈红敏博士及MIT科学家赖才达博士、王文首博士于2020年联合创立，核心定位是AI药物递送——利用人工智能技术设计纳米材料，将药物精准递送至人体特定器官和组织。其自研的NanoForge平台是全球首个AI纳米递送平台，衍生出AiTEM/AiLNP/AiRNA三大解决方案，可将制剂开发时间从1–2年缩短到2–3个月，已实现对肝脏、肌肉、肿瘤等8个关键器官的精准靶向递送。 拥有超过10个候选产品，其中3个处于临床阶段、1个接近pre-NDA（MTS-004），另有早期管线与动物保健方向布局； MTS-004：中国首个完成III期试验的AI赋能制剂创新药（适应症为假性延髓情绪失控PBA），2025年对外授权获得约1亿元首付款，标志着平台价值得到产业端认可； 财务表现： 2022-2024年营收分别为55.4万元、933.8万元、148.2万元，呈现剧烈波动，2024年同比大幅下滑8","plainDigest":"$剂泰科技-P(07666)$ $英派药业-B(07630)$ 基本情况： 申购时间：5月5日-5月8日，11号出结果，12号暗盘，13号上市； 发行价格：10.5 入场费：5302.95 1手：500股 全球发售：2.01亿股 回拨5%：公开发售：1006.15万股，发行手数：20123手； 回拨10%：公开发售：2012.30万股，发行手数：40246手； 回拨20%：公开发售：4024.60万股，发行手数：80492手； 基石：有，18家基石投资者认购54.84%份额 绿鞋：有，中信里昂稳价 保荐人：富瑞、德意志、中信联合保荐 分配机制：18C机制A，最高回拨20% 剂泰科技是一家人工智能驱动纳米材料创新的生物科技公司，由美国工程院院士陈红敏博士及MIT科学家赖才达博士、王文首博士于2020年联合创立，核心定位是AI药物递送——利用人工智能技术设计纳米材料，将药物精准递送至人体特定器官和组织。其自研的NanoForge平台是全球首个AI纳米递送平台，衍生出AiTEM/AiLNP/AiRNA三大解决方案，可将制剂开发时间从1–2年缩短到2–3个月，已实现对肝脏、肌肉、肿瘤等8个关键器官的精准靶向递送。 拥有超过10个候选产品，其中3个处于临床阶段、1个接近pre-NDA（MTS-004），另有早期管线与动物保健方向布局； MTS-004：中国首个完成III期试验的AI赋能制剂创新药（适应症为假性延髓情绪失控PBA），2025年对外授权获得约1亿元首付款，标志着平台价值得到产业端认可； 财务表现： 2022-2024年营收分别为55.4万元、933.8万元、148.2万元，呈现剧烈波动，2024年同比大幅下滑8","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778060861737,"gmtModify":1778062281353,"symbols":["07666","07630"],"themeIds":["a302bd33c5cb41d08ef3c9accf03faa3"],"popularizeThemeFlag":false,"imageCount":6,"images":[{"url":"https://static.tigerbbs.com/e94b0174ba32da2f83d42c4d6438aa4b","width":"591","height":"781"},{"url":"https://static.tigerbbs.com/89abc14e3356192f3c9db3bba728cc48","width":"840","height":"775"},{"url":"https://static.tigerbbs.com/d33008fb9b766c2f6f839943b9215bee","width":"1080","height":"2164"}],"repostCount":1,"viewCount":12662,"likeCount":4,"liked":false,"collected":false,"commentCount":6,"hotComments":[{"id":"561977963644896","author":{"authorId":"3473824220208426","idStr":"3473824220208426","name":"百胜医疗","avatar":"https://static.tigerbbs.com/3a5c9c3dc67fa13fc82ca603e09f9bfb","userType":1,"introduction":"","crmLevel":9,"crmLevelSwitch":1,"fanSize":228,"starInvestorFlag":false},"content":"乙尾能中4手么？","plainContent":"乙尾能中4手么？","likeCount":0,"commentType":"valid","coins":0},{"id":"561284537686144","author":{"authorId":"9000000000000701","idStr":"9000000000000701","name":"AthenaVeblen","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false},"content":"实验室视角看挺硬核 中签率咋算","plainContent":"实验室视角看挺硬核 中签率咋算","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561271109853472","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2871,"displayRows":4,"foldSize":0,"authorId":"4204409696979492"}]},{"cardType":"TWEET","cardId":"TWEET.561494969677776","cardData":[{"tweetId":"561494969677776","author":{"authorId":"4204409696979492","idStr":"4204409696979492","name":"101可转债","avatar":"https://static.tigerbbs.com/e9fd1abc154a52b8356f64c64f49564d","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","templateUuid":"a97bce155cb14045be40c3fe246e8d20","name":"Emerging Contributor","description":"Contributors who received Editor's Pick for the 1st time","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.13","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.08","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","name":"新晋创作者","description":"首次获得精华帖的创作者","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":404,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"港股新股打新：英派药业-B (07630.HK) 值不值得打？怎么打？","digest":"<a target=\"_blank\" href=\"https://laohu8.com/S/07630\">$英派药业-B(07630)$</a> <a href=\"https://laohu8.com/S/07666\">$剂泰科技-P(07666)$</a> <a href=\"https://laohu8.com/S/01236\">$乐动机器人(01236)$</a> 基本情况： 申购时间：5月5日-5月8日，11号出结果，12号暗盘，13号上市； 发行价格：19.75-21.75 入场费：4393.88 1手：200股 全球发售：4197.70万股 公开发售：419.78万股 发行手数：20989手； 基石：有，8家基石投资者认购32.15%份额 绿鞋：有，高盛稳价 保荐人：高盛和中金联合保荐 分配机制：机制B，回拨10% 英派药业成立于2009年，是一家专注于合成致死精准抗癌疗法的生物技术公司。其核心产品塞纳帕利（商品名：派舒宁®）已于2025年1月获NMPA批准上市，作为卵巢癌一线维持疗法覆盖全人群，并于2025年12月纳入国家医保目录。 全球仅有三家企业同时拥有商业化阶段PARP1/2抑制剂和临床阶段新一代PARP1选择性抑制剂，合成致死赛道的稀缺标的。 研发管线上，公司拥有1款商业化产品、4款临床阶段产品、7款临床前产品，覆盖PARP、ATR、WEE1、ADC、蛋白降解剂等方向。 财务表现： 2024-2025年营收约0.336、0.383亿元人民币，同比增长14%；收入主要源于授权费及少量的产品销售。 同期净利润分别-2.55、-2.96亿元，亏损主要来自研发与优先股负债利息，毛利率约95%。 2024-2025年研发开支约1.8-1.95亿元，研发投入高。 募资用途： 约51%用于核心产品塞纳帕利临床开发及商业化； 约31%用于IMP1734及IMP9064临","plainDigest":"$英派药业-B(07630)$ $剂泰科技-P(07666)$ $乐动机器人(01236)$ 基本情况： 申购时间：5月5日-5月8日，11号出结果，12号暗盘，13号上市； 发行价格：19.75-21.75 入场费：4393.88 1手：200股 全球发售：4197.70万股 公开发售：419.78万股 发行手数：20989手； 基石：有，8家基石投资者认购32.15%份额 绿鞋：有，高盛稳价 保荐人：高盛和中金联合保荐 分配机制：机制B，回拨10% 英派药业成立于2009年，是一家专注于合成致死精准抗癌疗法的生物技术公司。其核心产品塞纳帕利（商品名：派舒宁®）已于2025年1月获NMPA批准上市，作为卵巢癌一线维持疗法覆盖全人群，并于2025年12月纳入国家医保目录。 全球仅有三家企业同时拥有商业化阶段PARP1/2抑制剂和临床阶段新一代PARP1选择性抑制剂，合成致死赛道的稀缺标的。 研发管线上，公司拥有1款商业化产品、4款临床阶段产品、7款临床前产品，覆盖PARP、ATR、WEE1、ADC、蛋白降解剂等方向。 财务表现： 2024-2025年营收约0.336、0.383亿元人民币，同比增长14%；收入主要源于授权费及少量的产品销售。 同期净利润分别-2.55、-2.96亿元，亏损主要来自研发与优先股负债利息，毛利率约95%。 2024-2025年研发开支约1.8-1.95亿元，研发投入高。 募资用途： 约51%用于核心产品塞纳帕利临床开发及商业化； 约31%用于IMP1734及IMP9064临","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1778115511036,"gmtModify":1778135410093,"symbols":["07666","01236","07630"],"themeIds":["e4363384c4254650b897c0f13fe1588f"],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/8b8b576a2f491df3b41af8fa527490f4","width":"592","height":"787"},{"url":"https://static.tigerbbs.com/40495e14d43c1fc702b249253806e60b","width":"911","height":"774"},{"url":"https://static.tigerbbs.com/ad45c595e139affa30acab20b38a90ff","width":"1080","height":"1212"}],"repostCount":2,"viewCount":10659,"likeCount":4,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/561494969677776","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2174,"displayRows":4,"foldSize":0,"authorId":"4204409696979492"}]}],"size":9},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"21208529","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7oQcNhh8av","pdf_url":"https://static.tigerbbs.com/2413d0c5a0f44f91b5bdc3048c47d136","pub_time":1777933080000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"07630","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0505/2026050500024_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2026-05-05 06:18","pubTimestamp":1777933080,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"https://www.impacttherapeutics.com/","compareEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0601},{"period":"3month","weight":0.0025},{"period":"6month","weight":0.0147},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.0388}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英派药业致力于研发具有自主知识产权的靶向抗癌创新药,专注于合成致死作用机制。公司以DNA损伤修复通路(DDR)自主研发产品为基础,构建了全球生物医药公司中覆盖面最广的DDR产品管线之一,并且正在逐步拓展到更多的全新的合成致死靶点。\n公司管线包括PARP抑制剂塞纳帕利(Senaparib/IMP4297)、Wee1抑制剂(IMP7068)、ATR抑制剂(IMP9064)、PARP1选择性抑制剂(IMP1734,与美国Eikon Therapeutics合作开发)以及多个其他DDR靶点抑制剂。其中最成熟的研发项目PARP抑制剂塞纳帕利在全球范围包含中国已开展卵巢癌、小细胞肺癌等适应症的临床II/III期研究。塞纳帕利用于晚期卵巢癌全人群一线维持治疗的III期临床研究(FLAMES)已达到主要研究终点,显示了同类最佳的药效和安全性。基于FLAMES研究成果,中国国家药监局(NMPA)已于2025年1月批准了塞纳帕利的新药上市申请。Wee1抑制剂IMP7068和ATR抑制剂IMP9064已在包括美国、中国在内的全球多个国家及地区开展I期临床研究,确定了临床II期推荐剂量(RP2D)。PARP1选择性抑制剂IMP1734已经获得FDA和NMPA的临床试验许可,在2024年初完成第一例患者入组。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"aProfile":null}}}